医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cytori Appoints VP and General Manager of Cell Therapy

2015年09月08日 PM09:00
このエントリーをはてなブックマークに追加


 

SAN DIEGO

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that Mr. John D. Harris has been appointed as Vice President and General Manager of Cell Therapy, a newly created role to be based in Tokyo, Japan. The role will focus on growth and development of the company’s existing and future global cell therapy commercial operations. Mr. Harris’ start date is set for October 1st, 2015.

“Cytori has recruited a very accomplished executive to help us optimally position our therapeutic platform in the existing market, evaluate future global opportunities and to ensure we are prepared to transition to full commercial launch of our late-stage clinical programs,” said Dr. Marc H. Hedrick, President and CEO of Cytori. “John is uniquely qualified for this role for a number of reasons, including his demonstrated leadership capabilities, familiarity with the Japanese & Asia-Pacific markets, and his first-hand knowledge of global cell therapy trends and opportunities.”

Mr. Harris joins Cytori from Becton Dickinson, where he serves as President of Becton Dickinson’s Japanese operations, which include a production facility, over 550 employees, and approximately $315 million in revenues.

“I have followed the steady emergence of the cell therapy sector as well as its clinical and regulatory evolution for a number of years as both an executive at Becton Dickinson as well as a member of related industry groups here in Japan,” said Mr. Harris. “It is my view that Cytori has the most promising technology platform in the sector and I am ready to help lead the company to become one of the first companies to bring cell therapy to market, both here in Japan and globally.”

Prior to his current leadership role at Becton Dickinson, Mr. Harris served as the business director of Becton Dickinson’s Medical Systems business unit and shortly thereafter also assumed the lead of the Preanalytical Systems business unit. Prior to joining BD, he functioned in key leadership positions with several healthcare and technology-related companies in the U.S., including Tyco Electronics (Asia Medical Sales Director), Delphi Medical Systems (Global Business Development Manager), and Kimberly-Clark/Ballard Medical Products (Senior Business Development Manager). Mr. Harris speaks fluent Japanese and currently resides in Japan with his wife and children.

In addition to his various corporate roles, Mr. Harris is a member of the Board of Governors of the American Chamber of Commerce in Japan (ACCJ) and a member of the Executive Committee of the American Medical Device & Diagnostics Association (AMDD), where he chairs the regenerative medicine working group.

Mr. Harris holds Master of Business Administration (MBA) and Bachelor of Arts (BA) degrees from University of Utah.

About Cytori Therapeutics, Inc.

Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information: visit www.cytori.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150908005630/en/

CONTACT

Cytori Therapeutics, Inc.
Tiago Girao, 1-858-458-0900
ir@cytori.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Clover Biopharmaceuticals Completes RMB 62.8 Million Series A Financing
  • 三叶草生物制药完成6,280万元人民币A轮融资
  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表